Peptides for Weight Loss: What the Evidence Actually Shows

“Peptides for weight loss” is a label that lumps together very different things: approved prescription medicines tested in tens of thousands of people, investigational drugs still in late-stage trials, and compounds promoted online with little or no human evidence. A peptide is simply a short chain of amino acids (see What Are Peptides?), so the word on its own says nothing about whether a product works or is safe.

The clearest way to answer the question is by evidence, not by popularity. This guide sorts weight-loss peptides into three tiers:

• Tier 1, approved medicines: peptides such as semaglutide, tirzepatide and liraglutide, each supported by large randomised controlled trials and approved by the U.S. Food and Drug Administration (FDA) for chronic weight management, plus setmelanotide for specific rare genetic forms of obesity.
• Tier 2, late-stage investigational peptides: molecules such as retatrutide, CagriSema (cagrilintide with semaglutide), survodutide and amycretin, which have phase 3 or earlier trial results but no approval yet.
• Tier 3, peptides promoted online: compounds such as AOD-9604 and MOTS-c, whose weight-loss claims rest mainly on animal studies or unpublished, unsuccessful human trials, and tesamorelin, an approved medicine whose approval covers a narrow indication rather than general weight loss.

When people ask for the “best peptides for weight loss”, the honest answer is that only Tier 1 has the evidence needed to judge benefit and harm. Ranking a Tier 3 compound alongside an approved medicine mixes two entirely different kinds of evidence. This guide describes research and regulatory status only. It gives no doses or instructions and is not medical advice.

Most peptides with strong weight-loss evidence copy or extend gut and brain hormones that regulate appetite. The central example is GLP-1 (glucagon-like peptide-1), which the gut releases after eating. At the levels reached with medicines, GLP-1 receptor agonists reduce appetite and food intake, mainly through actions in the brain, and slow stomach emptying. The body's own GLP-1 is inactivated within minutes, so medicines such as semaglutide are modified to last far longer; the chemistry is explained in Peptide Half-Life, and the hormone background in The Incretin Effect.

Newer molecules add further hormone targets in a single peptide or combination:

• GIP plus GLP-1: tirzepatide activates both receptors.
• Glucagon plus GLP-1: survodutide is designed to add the energy-use and liver effects of glucagon receptor activity.
• GIP, GLP-1 and glucagon: retatrutide acts on all three.
• Amylin plus GLP-1: CagriSema combines an amylin analogue with semaglutide; amycretin puts both activities in one molecule.

Why combining receptors might add benefit is covered in Multi-Receptor Agonists. A different route is the melanocortin-4 (MC4) receptor in the hypothalamus, part of the brain's long-term weight-control circuit. Setmelanotide activates this receptor and is designed for people whose obesity results from specific genetic breaks in that pathway (see Melanocortin Receptors).

Compounds in Tier 3 are usually described with very different mechanisms, such as directly “burning fat” or mimicking exercise. Those descriptions mostly come from cell and animal work, and a plausible mechanism is not the same as evidence of weight loss in people (see Human vs Preclinical Research).

Three peptide medicines are approved in the United States for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity. Each approval rests on randomised, double-blind, placebo-controlled trials.

• Liraglutide (Saxenda) was approved for weight management in December 2014 [1]. In the 56-week SCALE trial of 3,731 adults without diabetes, 63.2% of people on liraglutide lost at least 5% of their body weight, compared with 27.1% on placebo; average loss was about 8.4 kg versus 2.8 kg [2].
• Semaglutide (Wegovy) was approved for weight management in June 2021 [3]. In STEP 1, average body weight fell by 14.9% over 68 weeks with semaglutide versus 2.4% with placebo. Gastrointestinal side effects such as nausea and diarrhoea were the most common, and 4.5% stopped treatment because of them, versus 0.8% on placebo [4]. A tablet form was approved for weight management in December 2025; see Oral vs Injected Peptides.
• Tirzepatide (Zepbound) was approved for weight management in November 2023 [5]. In SURMOUNT-1, average weight change over 72 weeks ranged from −15.0% to −20.9% across the tested doses, versus −3.1% with placebo [6].

For semaglutide there is also outcome evidence beyond the scales. The SELECT trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Over a mean follow-up of more than three years, the combined rate of cardiovascular death, heart attack or stroke was 6.5% with semaglutide versus 8.0% with placebo, a hazard ratio of 0.80. Stopping the study drug because of adverse events was also more common with semaglutide (16.6% versus 8.2%) [7].

Setmelanotide (Imcivree) is a different case. It is approved to reduce excess body weight in people with obesity caused by specific genetic conditions, including POMC, PCSK1 or LEPR deficiency confirmed by genetic testing and Bardet-Biedl syndrome, and more recently acquired hypothalamic obesity. Its label states that it is not expected to work in other types of obesity [8]. In its pivotal single-arm trials, 8 of 10 participants with POMC deficiency and 5 of 11 with LEPR deficiency lost at least 10% of their weight at about one year [9]. These trials were small because the conditions are rare.

The following peptides have published trial results but were not approved by the FDA for any use as of 17 October 2026, the date this status was checked. Results come from different trials with different populations, durations and analysis methods, so the numbers should not be lined up as a ranking.

• Retatrutide (Eli Lilly; GIP, GLP-1 and glucagon receptors). In the phase 3 TRIUMPH-1 trial of 2,339 adults with obesity and without diabetes, average weight change over 80 weeks was −17.6% to −25.0% across dose groups, versus −3.9% with placebo; the most common adverse events were gastrointestinal [10].
• CagriSema (Novo Nordisk; cagrilintide plus semaglutide). In REDEFINE 1, 3,417 adults without diabetes were randomised; average weight change over 68 weeks was −20.4% versus −3.0% with placebo, and gastrointestinal adverse events affected 79.6% versus 39.9% [11]. The company submitted CagriSema to the FDA in December 2025 and said a decision was anticipated by late 2026. The same announcement reported that REDEFINE 4, a head-to-head trial, did not show CagriSema to be non-inferior to tirzepatide [12]. No FDA decision had been announced when this guide was checked.
• Survodutide (Boehringer Ingelheim; glucagon and GLP-1 receptors). In the phase 3 SYNCHRONIZE-1 trial of 725 adults without diabetes, average weight change at 76 weeks was −12.2% and −13.0% in the two dose groups, versus −5.4% with placebo. Gastrointestinal symptoms occurred in 80.9% and 89.7% of the survodutide groups, versus 47.9% with placebo [13].
• Amycretin (Novo Nordisk; GLP-1 and amylin receptors in one molecule). A phase 1b/2a study randomised 125 people; in the highest-dose group, average weight change at 36 weeks was −24.3% versus −1.1% with placebo, but group sizes were small and many participants withdrew [14]. A phase 3 trial, AMAZE 1, began in February 2026 and is recruiting [15].

Investigational means exactly that: approval is not guaranteed, and regulators weigh side effects and tolerability as well as weight loss. Products marketed online under these names have not been tested in these trials. For a dated, regularly updated status summary, see Orforglipron, Retatrutide and CagriSema: Where the Next Weight-Loss Drugs Stand.

Several peptides are widely promoted for fat loss without approval and without convincing human trials. What the evidence actually shows differs for each one.

• AOD-9604 is a modified fragment of human growth hormone. Its developer ran human obesity trials in the 2000s, mostly with an oral form, but they were never published in full. In a 2024 briefing document, the FDA reviewed the available summaries and concluded that “there is a lack of evidence to support the effectiveness” of AOD-9604 for obesity “for any” route of administration. In most of the studies it identified, AOD-9604 failed to show a benefit over placebo, and it found no human exposure data for the injected or skin routes [16].
• MOTS-c is a peptide encoded in mitochondrial DNA. In the 2015 study that described it, treatment in mice prevented diet-induced obesity and insulin resistance [17]. There are no published randomised trials of MOTS-c for weight loss in people. A small phase 2a trial registered in 2026 is recruiting adults with prediabetes and overweight or obesity; its main outcome is insulin sensitivity, not weight, and no results are available [18].
• Tesamorelin is an approved medicine, but not a general weight-loss drug. It stimulates the body's release of growth hormone and was approved in 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. In a 26-week trial in that population, visceral (deep abdominal) fat fell by 15.2% with tesamorelin and rose by 5.0% with placebo [19]. Its current label states that it “is not indicated for weight loss management as it has a weight neutral effect” [20].

The gap between these compounds and Tier 1 is not a matter of degree. Approved medicines have large, published, placebo-controlled trials with defined products. Tier 3 claims usually rely on animal studies, mechanism stories, unpublished data or results from a different population. Products labelled “research use only” are not made or tested to medicine standards; see what “research use only” means and approved versus unapproved peptides.

The table summarises each compound's U.S. status on 17 October 2026 and the strongest human evidence found for weight loss. It is a summary of evidence, not a recommendation.

“RCT” means randomised controlled trial, the study design that best isolates a medicine's effect (see Randomized Controlled Trials).

Safety depends on the specific product, and evidence about safety comes from the same trials as evidence about benefit. For approved medicines, side effects are measured in thousands of trial participants, listed in the label and tracked after approval. For Tier 1 incretin medicines, the most common problems in trials were gastrointestinal: nausea, vomiting, diarrhoea and constipation [4][6]. More serious risks, such as gallbladder and pancreas problems, and a boxed warning about thyroid C-cell tumours seen in rodents, are set out in the prescribing information [21]. Whether a given medicine is suitable for a given person is a decision for a licensed clinician.

For Tier 2 peptides, safety is still being characterised, which is one reason they are not yet approved. For Tier 3, the safety question is largely unanswered: there are few or no controlled human data, and products marketed outside the medicine supply chain may differ from what their label says in identity, purity or sterility (see peptide impurities).

Two further points apply across the board. First, weight usually returns when effective medicines are stopped; the evidence is reviewed in Stopping Semaglutide or Tirzepatide. Second, a larger average weight loss in one trial does not make a medicine “better” for everyone; tolerability, other health conditions and the way results were analysed all matter.

What are the best peptides for weight loss?

Ranked by strength of evidence rather than recommendation, the peptides with the strongest human evidence are the approved medicines semaglutide, tirzepatide and liraglutide, each tested in large randomised trials [4][2][6]. Retatrutide, CagriSema, survodutide and amycretin have trial results but remain investigational. Peptides such as AOD-9604 and MOTS-c lack convincing human evidence [16][18]. Which medicine, if any, suits an individual is a question for a clinician.

How do peptides work for weight loss?

The best-studied ones mimic gut hormones such as GLP-1, GIP and amylin, which reduce appetite and food intake through actions in the brain and slow stomach emptying. Setmelanotide instead activates the MC4 receptor in a brain pathway that is broken in certain genetic forms of obesity [9].

Are peptides safe for weight loss?

Approved peptide medicines have known, labelled side effects, most commonly gastrointestinal ones, measured in large trials [4][6]. Unapproved peptides have little or no controlled safety data, and their product quality is not assured.

Is semaglutide (Ozempic or Wegovy) a peptide?

Yes. Semaglutide is a modified version of the human GLP-1 peptide. Ozempic is the brand approved for type 2 diabetes, and Wegovy is the brand approved for weight management [3]. So “peptides vs Ozempic” is not a contest between two categories: Ozempic is itself a peptide medicine. The real contrast is between approved peptide medicines and unapproved peptides with little evidence.

Do weight-loss peptides work without injections?

Some do. A semaglutide tablet is approved, but taking peptides by mouth is difficult, and most unapproved “oral” products have no supporting trials. See Oral vs Injected Peptides.